Local low-dose IL-2 therapy

Hepato-Gastroenterology

Volumn 46, Issue SUPPL. 1, 1999, Pages 1280-1286

  Den Otter, Willem ^a,d   Balemans, Lianne ^d   Battermann, Jan J ^b   Bernsen, Monique R ^a   Cadee, Jenny A ^a   Dobrowolski, Zygmunt ^e   Everse, Linda A ^a   Fiszer Maliszewska, Lucja ^c   Gavhumende, Richard ^g   De Groot, Jan Willem ^a   De Groot, Kees ^a   Hennink, Wim E ^a   Hill, F W Graham ^g   Jurgenliemp Schulz, Ina ^b   Klein, Wim R ^a   Koten, Jan Willem ^a   Maas, Riks A ^a   Steerenberg, Peter ^d   Stewart, Rachel ^g   Zembala, Marek ^f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^d RIVM ^*  (Netherlands)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

Animals; Cancer; Interleukin 2; Low dose; Treatment

Indexed keywords

CISPLATIN; INTERLEUKIN 2;

CANCER; CELL INFILTRATION; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; HUMAN; METASTASIS; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CATTLE; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; LYMPHOMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033049083     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W: Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 1991; 33:389-394.
2. Den Otter W, De Groot JW, Bernsen MR, Heintz APM, Maas R, Hordijk GJ, Hill FWG, Klein WR, Ruitenberg EJ, Rutten VPMG: Optimal regimes for local IL-2 tumour therapy. Int J Cancer 1996; 88:400-403.
3. Maas RA, Dullens HFJ, De Jong WH, Den Otter W: Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 1989; 49:7037-7040.
4. Den Otter W, Hill FWG, Klein WR, Koten J-W, Steerenberg PA, De Mulder PHM, Rutten VPMG, Ruitenberg EJ: Low doses of Interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 1993; 13:2453-2456.
5. Den Otter W, Balemans LTM, Bernsen MR, Everse LA, Fiszer-Malizewska L, De Mulder PHM, Hill FWG, Klein WR, Koten JW, Maas RA, Van der Meijden APM, Ruitenberg EJ, Rutten VPMG, Steerenberg PA, Stewart RJ: IL-2 therapy of cancer. Why are therapeutic effects in animals better than in man. (submitted for publication)
6. Everse LA, Renes B, Jurgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ: Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int J Cancer 1997; 72:1003-1007.
7. Mattijssen V, Balemans LTM, Steerenberg PA, De Mulder PHM: Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea pig tumours. Int J Cancer 1992; 51:812-817.
8. Balemans LTM, Steerenberg PA, Koppenhagen FJ, Kremer BHA, De Mulder PHM, Claessen AME, Scheper RJ, Den Otter W: PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumour and beneficial effect of cyclophosphamide. Int J Cancer 1994; 58:871-876.
9. Bernsen MR, Van Der Velden AW, Everse LA, Dullens HFJ, Den Otter W, Heintz AHM: Interleukin-2: Hope in cases of Cisplatin resistant tumours. Cancer Immunol Immunother 1998; 46:41-47.
10. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Ruitenberg EJ, Rutten VPMG: Therapy of bovine ocular squamous cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 1995; 41:10-14.
11. Hill FWG, Klein WR, Hoyer MJ, Rutten VPMG, Kock N, Koten JW, Steerenberg PA, Ruitenberg EJ, Den Otter W: Anti effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 1994; 41:19-29.
12. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M: Intravesical IL-2 to treat T1 papillary bladder carcinoma: regression of marker lesion in 8 out of 10 patients. J Urol 1998; 159:1183-1180.
13. Bernsen M: Local chemo-immunotherapy with low doses of Cisplatin and recombinant Interleukin-2 in three murine models. Thesis, Utrecht, 1993.
14. Den Otter W, De Groot CJ, Hennink WE: Effective cancer therapy with single injection of IL-2. (submitted for publication)
15. Bernsen MR, Dullens HFJ, Den Otter W, Heintz APM: Re-evaluation of the superiority of polyethylene glycol-modified Interleukin-2 over regular recombinant Interleukm-2. J Interferon and Cytokine Res 1995; 15:641-645.